查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1470383

尿道感染感染市场：按治疗方法、最终用户分类 - 全球预测 2024-2030

Urinary Tract Infection Market by Clinical Indication (Cystitis, Pyelonephritis, Urethritis), Treatment (Diagnosis, Therapatics), End User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

尿道感染市场规模预计 2023 年为 116.7 亿美元，2024 年达到 124.7 亿美元，预计 2030 年将达到 186.7 亿美元，复合年增长率为 6.93%。

尿道感染，通常称为 UTI，是指影响泌尿器官系统任何部位的细菌感染，包括肾臟、输尿管、膀胱和尿道。大多数细菌感染疾病会影响下泌尿道，包括膀胱和尿道。由于其解剖结构，女性患尿道结石的风险高于男性。如果不及时治疗，尿道结石会导致更严重的併发症，包括肾臟损伤。该市场包括抗生素治疗、疼痛管理药物、诊断测试（尿液培养和敏感性测试）、医疗设备（导尿管）和预防解决方案（预防尿道结石復发的抗生素）。由于社会老化以及糖尿病、肾结石等尿道结石高风险疾病的增加，迫切需要尿道结石的诊断和治疗药物。然而，诊断方法的敏感性和准确性有限以及多重抗药性尿道结石细菌的日益流行引起了人们对尿道感染诊断方法和治疗策略的可靠性和有效性的担忧。然而，各大公司正在开发具有新作用机制的抗生素来对抗抗生素抗药性。此外，透过快速、家庭或护理点检测解决方案增强诊断也正在取得进展，以实现及时、准确的尿道结石检测和管理。新兴趋势还包括采用远端医疗咨询和数位健康平台来管理和预防尿道结石。

主要市场统计
基准年[2023] 116.7亿美元
预测年份 [2024] 124.7亿美元
预测年份 [2030] 186.7亿美元
复合年增长率（%） 6.93%

治疗有临床症状的肾盂肾炎需要强大且先进的药物策略

膀胱炎是膀胱的发炎，主要是细菌感染引起的。症状包括尿急感、频尿和排尿困难。治疗通常涉及短期抗生素治疗，但第一线药物是首选，因为它们有效且促进抗生素抗药性的风险较低。肾盂肾炎是尿道结石的一种更严重的形式，涉及肾组织感染。症状更严重，包括发烧、腰部疼痛和噁心。治疗通常需要使用更强的抗生素，最初可以静脉注射。尿道炎是尿道的发炎，通常由细菌或病毒感染引起。症状包括尿道分泌物和搔痒。治疗方法取决于致病细菌；抗生素用于治疗细菌感染，抗病毒药物用于治疗病毒感染。

最终用户：随着远端医疗和电子医疗平台的普及，改善自我管理解决方案的最新进展

医院是尿道结石治疗市场的重要组成部分。医院通常是需要即时就医的严重和复杂尿道结石例的第一个接触点。医院需要采用诊断和治疗方法的综合方法来管理尿道结石。医院提供的诊断服务包括尿液培养、敏感性测试和先进的分子诊断。治疗通常涉及静脉注射抗生素。自我管理治疗针对的是喜欢在家治疗的轻至中度尿道结石患者。由于店面销售(OTC) 和电子医疗解决方案的便利性和可用性不断提高，该行业正在经历显着增长。该部门包括电子健康解决方案和数位平台，透过远端医疗和线上处方服务提供尿道结石管理。

区域洞察

以美国和加拿大为中心的美洲地区在研究、诊断开发和创新治疗方面领先于尿道结石市场。尿道结石的高盛行率，加上强大的医疗基础设施和患者意识，推动了对尿道结石的先进诊断和治疗的需求。我们观察到对专注于下一代抗生素和非抗生素方法的生物技术公司的大量投资。美国最近的专利包括新的诊断方法和先进的药物传输系统，旨在改善患者的治疗结果并降低復发率。由于不同的医疗政策和进入方式，欧盟国家呈现出不同的市场动态。然而，一个通用的趋势是增加对抗菌素抗药性研究和新治疗方法开发的资助。欧盟对抗抗生素抗药性感染疾病的承诺包括对针对尿道结石的研究和创新计划进行大量投资。此外，远端医疗和电子医疗服务的引入增加了患者接受尿道结石治疗的机会。此外，与临床诊断和治疗设备的开发相关的严格法规的存在，为尿道结石诊断和治疗解决方案的开发和进步创造了标准化的环境。亚太地区尿道结石市场的特征是需求量大，对廉价治疗方法的认识也不断增强。政府的医疗保健倡议和蓬勃发展的学名药行业正在推动成长。在日本、中国和印度等国家，许多研究都集中在治疗尿道结石的草药和替代药物上，以回应消费者对非化学替代品的偏好。

FPNV定位矩阵

FPNV 定位矩阵对于评估尿道感染市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对尿道感染市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.尿道感染市场的市场规模与预测是多少？

2.在尿道感染市场预测期间内，有哪些产品、细分市场、应用和领域需要考虑投资？

3.尿道感染市场的技术趋势和法规结构是什么？

4.尿道感染市场主要供应商的市场占有率为何？

5. 进入尿道感染市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 糖尿病和肾结石盛行率增加
      • 女性族群尿道感染率高
      • 过度使用抗生素和抗药性增加导致复杂的尿道感染
    • 抑制因素
      • Aminoglycosides和Azole等治疗药物的副作用
    • 机会
      • 加强新型抗生素、疫苗和设备的研究和开发
      • 公众意识和不断上涨的医疗费用
    • 任务
      • 与尿道感染相关的社会耻辱
  • 市场区隔分析
    • 临床适应症：需要强大且先进的药物治疗策略来治疗肾盂肾炎
    • 最终用户：随着远端医疗和电子健康平台的普及，在改进自我管理解决方案方面取得了最新进展
  • 市场趋势分析
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析
  • 客户客製化

第六章依临床适应症分類的尿道感染感染市场

  • 膀胱炎
  • 肾盂肾炎
  • 尿道炎

第七章尿道感染感染治疗市场

  • 诊断
  • 治疗药物

第八章尿道感染感染市场：依最终用户分类

  • 医院
  • 自我管理

第九章美洲尿道感染市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太尿道感染市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲尿道感染市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Vivoo 在 CES 2024 上推出家庭数位 UTI 测试
    • NRx Pharmaceuticals 宣布 FDA核准NRX-101 的临床实验申请 (IND)，NRX-101 是一种治疗复杂尿道感染
    • 英恆与美国军方合作开发治疗尿道感染的噬菌体

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-034B50030335

[187 Pages Report] The Urinary Tract Infection Market size was estimated at USD 11.67 billion in 2023 and expected to reach USD 12.47 billion in 2024, at a CAGR 6.93% to reach USD 18.67 billion by 2030.

A urinary tract infection, commonly termed a UTI, refers to a bacterial infection that affects any section of the urinary system, including the kidneys, ureters, bladder, and urethra. Most bacterial infections involve the lower urinary tract, which includes the bladder and the urethra. Women are at higher risk of developing a UTI than men due to their anatomy. If left untreated, a UTI can lead to more severe complications, including kidney damage. The market's scope encompasses antibiotic treatments, pain management medications, diagnostics tests (urine culture and sensitivity tests), medical devices (urinary catheters), and preventive solutions (prophylactic antibiotics for recurrent UTIs). A growth in the aging population and increasing incidences of conditions that are associated with a higher risk of developing UTIs, such as diabetes and kidney stones, has created an urgent need for UTI diagnostics and therapeutics. However, limitations with the sensitivity and accuracy of diagnostics procedures and the increasing prevalence of multi-drug resistant UTI pathogens raise concerns about the reliability and efficacy of urinary tract infection diagnostics and treatment strategies. However, key players are developing new antimicrobial agents with novel mechanisms of action to combat antibiotic resistance. Moreover, enhancing diagnostics with rapid, at-home, or point-of-care testing solutions to enable timely and accurate detection and management of UTIs is also gaining traction. Emerging trends also include the adoption of telemedicine consultations and digital health platforms aimed at UTI management and prevention.

KEY MARKET STATISTICS
Base Year [2023] USD 11.67 billion
Estimated Year [2024] USD 12.47 billion
Forecast Year [2030] USD 18.67 billion
CAGR (%) 6.93%

Clinical Indication: Need for potent and advanced medication strategies for the management of pyelonephritis

Cystitis represents inflammation of the bladder, predominantly due to bacterial infection. It manifests through symptoms such as urgency, frequency, and dysuria. Treatment usually involves a short course of antibiotics, with a preference for first-line agents considering their efficacy and low risk of promoting antibiotic resistance. A more severe form of UTI, pyelonephritis, involves infection of the kidney tissue. Symptoms are more intense, including fever, flank pain, and nausea. Treatment often necessitates the use of more potent antibiotics, potentially through intravenous (IV) routes initially. Urethritis involves inflammation of the urethra, typically caused by bacterial or viral infections. Presenting symptoms include urethral discharge and itching. The treatment depends on the causative agent, with antibiotics prescribed for bacterial infections and antivirals for viral causes.

End User: Recent advancements to improve self-administration solutions through the proliferation of telemedicine and e-health platforms

Hospitals represent a significant sector of the UTI treatment market. They are typically the first point of contact for severe and complicated UTI cases that require immediate medical attention. The need-based preference in hospitals includes a comprehensive approach to UTI management, utilizing both diagnostic and therapeutic modalities. Diagnostic services provided by hospitals include urine culture, susceptibility testing, and advanced molecular diagnostics. Treatment often involves the administration of intravenous antibiotics. Self-administered treatments cater to individuals with mild to moderate UTIs who prefer managing their condition at home. This sector has grown substantially, driven by the convenience and the increasing availability of over-the-counter (OTC) and e-health solutions. It can include e-health solutions and digital platforms offering UTI management through telemedicine and online prescription services.

Regional Insights

The Americas region, particularly the U.S. and Canada, leads in the UTI market in terms of research, diagnostic developments, and innovative treatments. The high prevalence of UTIs, coupled with strong healthcare infrastructure and patient awareness, drives the need for advanced diagnostics and therapeutic UTI procedures. Significant investments in biotechnology firms focusing on next-generation antibiotics and non-antibiotic approaches have been observed. Recent patents in the U.S. involve novel diagnostic methods and advanced drug delivery systems aimed at improving patient outcomes and reducing recurrence rates. EU countries exhibit diverse market dynamics due to varying healthcare policies and access. However, a common trend is the increasing research funding for antimicrobial resistance and the development of new treatment methods. The EU's commitment to combat antibiotic-resistant infections includes significant investment in research and innovation projects targeting UTIs. Moreover, the adoption of telemedicine and e-health services is enhancing patient accessibility to care for UTIs. Furthermore, the presence of stringent regulations pertaining to the development of clinical diagnostics and therapeutic devices has created a standardized landscape for the development and progress of UTI diagnostics and treatment solutions. APAC's UTI market is characterized by high demand for affordable treatments and increasing awareness. The growth is facilitated by government healthcare initiatives and a booming generic pharmaceuticals sector. Research in countries such as Japan, China, and India often focuses on herbal and alternative medicines for UTI treatment, catering to consumer preferences for non-chemical alternatives.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Urinary Tract Infection Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Urinary Tract Infection Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Urinary Tract Infection Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Almirall, S.A., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddys Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Shionogi & Co., Ltd., Siemens Healthcare AG, Sun Pharmaceutical Industries Limited, Sysmex Corporation, Teva Pharmaceutical Industries Ltd., URIT Medical Electronic Co., Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Urinary Tract Infection Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Clinical Indication
    • Cystitis
    • Pyelonephritis
    • Urethritis
  • Treatment
    • Diagnosis
    • Therapatics
      • Aminoglycosides
      • Azoles
      • Quinolones
      • B-lactam
  • End User
    • Hospitals
    • Self-Administered
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Urinary Tract Infection Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Urinary Tract Infection Market?

3. What are the technology trends and regulatory frameworks in the Urinary Tract Infection Market?

4. What is the market share of the leading vendors in the Urinary Tract Infection Market?

5. Which modes and strategic moves are suitable for entering the Urinary Tract Infection Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Prevalence of Diabetes and Kidney Stones
      • 5.1.1.2. High Incidences of UTI in Female Population
      • 5.1.1.3. Complicated UTI due to Rise in Excessive Use of Antibiotics and Drug-Resistance
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse Effects of Urinary Tract Infection Treatment Drugs such as Aminoglycosides and Azoles
    • 5.1.3. Opportunities
      • 5.1.3.1. Rise in R&D for a Novel Class of Antibiotics, Vaccines, and Devices
      • 5.1.3.2. Increase in Awareness among People and Healthcare Expenditure
    • 5.1.4. Challenges
      • 5.1.4.1. Social Stigma Concerning Urinary Tract Infections
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Clinical Indication: Need for potent and advanced medication strategies for the management of pyelonephritis
    • 5.2.2. End User: Recent advancements to improve self-administration solutions through the proliferation of telemedicine and e-health platforms
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis
  • 5.9. Client Customization

6. Urinary Tract Infection Market, by Clinical Indication

  • 6.1. Introduction
  • 6.2. Cystitis
  • 6.3. Pyelonephritis
  • 6.4. Urethritis

7. Urinary Tract Infection Market, by Treatment

  • 7.1. Introduction
  • 7.2. Diagnosis
  • 7.3. Therapatics

8. Urinary Tract Infection Market, by End User

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Self-Administered

9. Americas Urinary Tract Infection Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Urinary Tract Infection Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Urinary Tract Infection Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Vivoo launches at-home digital UTI test at CES 2024
    • 12.3.2. NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections
    • 12.3.3. Intron enters collaboration with the US Army on bacteriophages for urinary tract infections

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. URINARY TRACT INFECTION MARKET RESEARCH PROCESS
  • FIGURE 2. URINARY TRACT INFECTION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. URINARY TRACT INFECTION MARKET DYNAMICS
  • FIGURE 7. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. URINARY TRACT INFECTION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. URINARY TRACT INFECTION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. URINARY TRACT INFECTION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CYSTITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CYSTITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PYELONEPHRITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PYELONEPHRITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY URETHRITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY URETHRITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AZOLES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AZOLES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY QUINOLONES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY QUINOLONES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY B-LACTAM, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY B-LACTAM, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY SELF-ADMINISTERED, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY SELF-ADMINISTERED, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 38. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 47. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 48. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 49. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 50. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 51. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 52. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 55. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 56. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 57. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 58. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 59. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 60. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 63. CANADA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 64. CANADA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 65. CANADA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 66. CANADA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 67. CANADA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 68. CANADA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 71. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 72. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 73. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 74. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 75. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 76. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 79. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 80. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 81. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 82. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 100. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 102. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 104. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 107. CHINA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 108. CHINA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 109. CHINA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 110. CHINA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 111. CHINA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 112. CHINA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 115. INDIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 116. INDIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 117. INDIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 118. INDIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 119. INDIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 120. INDIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 123. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 124. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 125. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 126. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 127. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 128. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 131. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 132. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 133. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 134. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 135. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 136. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 139. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 140. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 141. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 142. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 143. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 144. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 148. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 150. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 152. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 155. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 156. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 157. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 158. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 159. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 160. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 164. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 166. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 171. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 172. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 173. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 174. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 175. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 176. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 179. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 180. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 181. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 182. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 183. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 184. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 187. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 188. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 189. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 190. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 191. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 192. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 205. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 206. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 207. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 208. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 209. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 210. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 213. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 214. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 215. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 216. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 217. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 218. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 221. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 222. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 223. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 224. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 225. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 226. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 229. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 230. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 231. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 232. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 233. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 234. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 237. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 238. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 239. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 240. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 241. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 242. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 245. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 246. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 247. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 248. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 249. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 250. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 253. ITALY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 254. ITALY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 255. ITALY URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 256. ITALY URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 257. ITALY URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 258. ITALY URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 262. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 264. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 266. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 269. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 270. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 271. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 272. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 273. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 274. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 277. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 278. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 279. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 280. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 281. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 282. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 285. POLAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 286. POLAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 287. POLAND URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 288. POLAND URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 289. POLAND URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 290. POLAND URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 293. QATAR URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 294. QATAR URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 295. QATAR URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 296. QATAR URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 297. QATAR URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 298. QATAR URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 299. QATAR URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 300. QATAR URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 301. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 302. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 303. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 304. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 305. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 306. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 307. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 308. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 310. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 312. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 314. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 316. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 318. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 320. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 322. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 324. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 325. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 326. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 327. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 328. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 329. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 330. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 331. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 332. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 333. SWEDEN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 334. SWEDEN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 335. SWEDEN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 336. SWEDEN URINARY